Physician profile
Eric Sigler
NPI 1447427067
$349,542.40
in general payments reported to CMS, 2019-2025
32 companies · $18K in 2025
The $18K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $59K · 2021: $93K · 2022: $70K · 2023: $31K · 2024: $62K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104K · Food and Beverage: $6,047 · Honoraria: $1,390 · Education: $87.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $103,702.33 |
| Food and Beverage | $6,046.96 |
| Honoraria | $1,390.00 |
| Education | $87.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $274,259.04 | 2020-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $51,740.32 | 2019-2025 | Eylea Hd, Eylea |
| Eyepoint US, INC. | $11,503.27 | 2020-2023 | |
| Mallinckrodt Enterprises LLC | $3,837.12 | 2019 | |
| Genentech USA, INC. | $3,341.72 | 2019-2025 | Vabysmo, Susvimo |
| Alimera Sciences, INC. | $1,563.00 | 2019-2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $555.52 | 2023-2025 | Izervay |
| Ani Pharmaceuticals, INC. | $402.24 | 2024-2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Biotissue Holdings INC. | $390.16 | 2022-2024 | |
| Apellis Pharmaceuticals, INC. | $269.57 | 2023-2025 | Syfovre |
| Abbvie INC. | $224.85 | 2022-2025 | Ozurdex |
| Sun Pharmaceutical Industries INC. | $220.97 | 2020-2025 | Cequa, Xelpros |
| Oculus Surgical INC. | $182.83 | 2023 | |
| Harrow Eye, LLC | $146.96 | 2025 | Iheezo |
| Novartis Pharmaceuticals Corporation | $129.48 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $122.19 | 2025 | Oxervate |
| Bausch & Lomb Americas INC. | $88.80 | 2022-2025 | Xipere, Visudyne |
| Alcon Vision LLC | $83.93 | 2023-2025 | Eysuvis, Simbrinza |
| Allergan, INC. | $76.97 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Revance Therapeutics, INC. | $61.95 | 2025 | Daxxify |
| Oyster Point Pharma, INC. | $56.41 | 2024-2025 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $54.12 | 2019-2020 | |
| Horizon Therapeutics Plc | $33.74 | 2020-2023 | Tepezza |
| Notal Vision, INC. | $22.40 | 2019 | |
| Amgen INC. | $21.71 | 2024 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $20.70 | 2023 | Tecnis Iol |
| Vyera Pharmaceuticals, LLC | $20.63 | 2019 | |
| Thea Pharma INC. | $14.58 | 2024 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $14.13 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $13.33 | 2024 | Xdemvy |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Sigler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.